DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0237501 A1 SHARP Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0237501 A1 SHARP Et Al US 2016O23750 1A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0237501 A1 SHARP et al. (43) Pub. Date: Aug. 18, 2016 (54) BIOMARKERS FOR DIAGNOSIS OF Related U.S. Application Data TRANSIENT SCHEMICATTACKS (62) Division of application No. 13/182,630, filed on Jul. (71) Applicant: The Regents of the University of 14, 2011, now abandoned. California, Oakland, CA (US) (60) Provisional application No. 61/364.334, filed on Jul. 14, 2010. (72) Inventors: Frank SHARP, Davis, CA (US); Xinhua ZHAN. Vacaville, CA (US); Publication Classification Glen C. JICKLING, Sacramento, CA (US): S. Claiborne JOHNSTON, San (51) Int. Cl. Francisco, CA (US) CI2O I/68 (2006.01) (52) U.S. Cl. (73) Assignee: The Regents of the University of CPC ........ CI2O 1688 (2013.0); CI2O 2600/158 California, Oakland, CA (US) (2013.01); C12O 2600/1 18 (2013.01) (57) ABSTRACT (21) Appl. No.: 15/043,577 The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient (22) Filed: Feb. 14, 2016 ischemic attacks (TIA). Patent Application Publication Aug. 18, 2016 Sheet 1 of 4 US 2016/0237SO1 A1 Standardized intensity s sis: iagnosis Controls xIA Figure IA-B Patent Application Publication Aug. 18, 2016 Sheet 2 of 4 US 2016/0237SO1 A1 & TA Cross-validated Probabilities (Thresholds 0.89) * Controls Controls TA ----------------------------------------------------------------------------------------------------------------------------------------- ... 0.9 O.8 O O 20 Subjects30 40 SO 50 Figure 2 Patent Application Publication Aug. 18, 2016 Sheet 3 of 4 US 2016/0237SO1 A1 Cross-validated Probabilities (Threshold=3.97) & TIA1 & A2 TIA1 T1A2 . .8 . 0. 4. O S O 20 25 Subjects Figure 3 Patent Application Publication Aug. 18, 2016 Sheet 4 of 4 US 2016/0237SO1 A1 FG. FG. A1 matrix metaliopeptidase 16 (MMP16) A2 matrix metaisopeptidase 16 (MMP16) 68. 8 8 p = 1.35E-7 p = 2.19E-7 g wis g 88: s 45: sess 456: s ge s esses xssess 8ss 888 sesses a: Controls A. As Controls A. A2 FG. FG. B1 matrix metallopeptidase 26 (MMP26) B2 atrix metallopeptile 26 (MMP26) 8.8; & siss s s e s s 2 as Controls A. As Contros A. A2 Figure 4A-B US 2016/02375O1 A1 Aug. 18, 2016 BOMARKERS FOR DIAGNOSIS OF present invention is based, in part, on gene expression profiles TRANSIENT SCHEMICATTACKS that provide insight into the immunological differences that exist in patients with TIAs. CROSS-REFERENCE TO RELATED APPLICATIONS BRIEF SUMMARY OF THE INVENTION 0001. This application is a divisional of U.S. application 0008. The present invention provides compositions and Ser. No. 13/182,630, filed on Jul. 14, 2011, which claims the methods for determining the occurrence, predicting the risk benefit of U.S. Provisional Application No. 61/364,334, filed of occurrence and predicting the cause of transient ischemic on Jul. 14, 2010, the entire disclosure of which is hereby attacks. incorporated herein by reference for all purposes. 0009. Accordingly, in one aspect, the invention provides methods for diagnosing a transientischemic attack (TIA) or a STATEMENT AS TO RIGHTS TO INVENTIONS predisposition for experiencing TIA, the method comprising: MADE UNDER FEDERALLY SPONSORED determining a level of expression of a plurality of TIA-asso RESEARCH AND DEVELOPMENT ciated biomarkers in a biological sample from a patient, wherein an increase or decrease of the level of expression 0002 This invention was made with Government support compared to a control indicates that the patient has suffered or under Grant No. NS056302, awarded by the National Insti is at risk of experiencing TIA, wherein the plurality of TIA tutes of Health. The government has certain rights in this associated biomarkers is selected from the biomarkers set invention. forth in Tables 1, 2, 5A, 5B, 5C, 5D, 7, 8 and 9. 0010. In some embodiments, the methods further com FIELD OF THE INVENTION prise obtaining a biological sample from the patient. In some 0003. The present invention provides methods and com embodiments, the biological sample is blood, serum or positions for diagnosing and predicting the risk and cause of plasma. transient ischemic attacks (TIA). 0011. In some embodiments, the determining step is per formed at 3 or fewer hours after a suspected ischemic event. BACKGROUND OF THE INVENTION In some embodiments, the determining step is performed at 3 or more hours after a suspected ischemic event, for example, 0004 Transient ischemic attacks (TIAS) are common, at about 6, 12, 24, 36, 48 or more hours after a suspected affecting over 300,000 persons per year in the United States ischemic event. In some embodiments, the determining step alone. Though TIA symptoms resolve by definition, TIAS are is performed at least 24 hours after a suspected ischemic far from benign. As many as 25% of TIA patients have recur event. rentischemic vascular events that occur within days to weeks 0012. In some embodiments, an increased expression following a TIA (1-3). Despite the high incidence and clinical level of one or more or all TIA-associated biomarkers importance, the development of therapies specifically tar selected from the group consisting of DKFZP434B061, geted toward TIA has been limited by the paucity of knowl FAM55D, FLJ30375, IGFBP5, LTER and SCN2A indicates edge regarding the underlying biology. Furthermore, the that the patient has suffered or is at risk of experiencing TIA. clinical diagnosis of TIA is imperfect and extensive evalua In some embodiments, an increased expression level of one or tion in those incorrectly diagnosed with TIA is costly (4). more or all TIA-associated biomarkers selected from the 0005 We have previously demonstrated that blood gene group consisting of GABRB2, ELAVL3, TWIST1, DPPA4, expression profiles in rats change following experimental DKFZP434P211, DLX6, ZNF479, ASTN2, SNX31, ischemic strokes and TIAS (5). Very brief focal ischemia in ALS2CR11, LOC440345 indicates that the patient has suf rats, simulating human TIA, elicits a dramatic change in brain fered or is at risk of experiencing TIA. tissue characterized by increased Heat Shock Protein 0013. In some embodiments, an increased expression (HSP70) expression, microglial activation and macrophage level of one or more or all TIA-associated biomarkers infiltration (6). This change in brain cellular function and selected from the group consisting of GABRB2, ELAVL3, inflammation alters blood immune cells, a process that can be COL1A1, SHOX2, GABRB2, TWIST1, DPPA4, detected using whole genome expression analysis (5). Fur DKFZP434P211, WIT1, SOX9, DLX6, ANXA3, EPHA3, thermore, the genes and associated functional pathways differ SOX11, SLC26A8, CCRL1, FREM2, STOX2, ZNF479, markedly between very brief focal ischemia and ischemic LOC338862, ASTN2, FOLH1, SNX31, KREMEN1, stroke (5). ZNF479, ALS2CR11, FIGN, RORB, LOC732096, GYPA, 0006 Human TIAS have also been associated with alter ALPL, LHX2, GALNT5, SRD5A2L2, GALNT14, OVOL2, ations in Systemic inflammation. TIA patients tend to have BMPR1B, UNC5B, ODZ2, ALPL, RASAL2, SHOX, elevated C-reactive protein (CRP) (7), IL-6, VCAM-1 and C19orf59, ZNF114, SRGAP1, ELAVL2, NCRNA00032, cytokine levels, as well as elevated leukocyte counts (8-10). LOC440345, FLJ30375, TFPI, PTGR1, ROBO1, NR2F2, Lp-PLA2, a marker of unstable atherosclerotic plaque, is also GRM5, LUM, FLJ39051, COL1A2, CASP5, OPCML, associated with TIA (11-12) as are fibrinogen (13-14) and TTC6, TFAP2B, CRISP2, SOX11, ANKRD30B, FLJ39051, D-Dimer (15). Whether such biological differences represent SCN2A, MYNN, FOXA2, DKFZP434B061, LOC645323, a cause or consequence of TIA remains unclear. However, SNIP, LOC645323, LOC374491, ADAM30, SIX3, better understanding of the pathophysiology represented by FLJ36144, CARD8, KREMEN1, RP1-127L4.6, FAM149A such differences will facilitate development of treatments B3GAT2, SPOCK3, G30, ITGBL1, IQGAP3, C7orfA5, targeted to TIA. ZNF608, LOC375010, LRP2, TGFB2, SHOX2, HOXC4/// 0007 Gene expression has been useful for identifying dif HOXC6, ELTD1, FAM182B///RP13-401N8.2, PROO478, ferences between patients with ischemic stroke and controls LIFR, FOLH1, EHF, NDST3, BRUNOL5, LOC728460, (16-18), but such studies have not been applied to TIA. The PDE1A, POU2AF1, FAT1, PCDH11X///PCDH11Y, US 2016/02375O1 A1 Aug. 18, 2016 FLJ37786, SLC22A4, DHRS13, EHF, MEG3, PIWIL1, MMP 19, MMP26, COL1A1, COL1A2, COL3A1, LOC203274, LOC100.133920///LOC286297, DMRT1, COL10A1, COL11A1, COL25A1, COL27A1, FGFs and ADM, VWA3B, GAFA3, HESX1, ADAMDEC1, CAV1, EGFR is increased in comparison to the control, and the LAMB4, TPTE, PPP1R1C, HPSE, AIM2, RUNDC3B, patient is determined to have atherosclerosis. CARD16, FAM124A, MGC39584, OSM, RFX2, MYBPC1, 0019. In some embodiments, the patient is exhibiting LTBR, C18orf2, SNRPN, FLJ36031, IL1B, TRPM1, symptoms of TIA. In some embodiments, the patient is OSTCL, MAPK14, KCNJ15///LOC100131955, FIGN, asymptomatic. HNT, S100A12, CHIT1, C7orf53, FAM13A1, GNAO1, 0020. In some embodiments, the methods further com MAPK14, FAM55D, PRKD2, LIMK2, C18orf54, IGFBP5, prise the step of providing an appropriate treatment or pre EVI1, PLSCR1, FOXC1, LOC646627, ZNF462, CNTLN, vention regime for TIA to the patient. ZNF438, DEFB105A///DEFB105B, LOC34.0017, C1orf67, 0021. In some embodiments, the level of expression of the ACSL1, ADH1B, SLC2A14///SLC2A3, IL1B, ST3GAL4, biomarker is determined at the transcriptional level. For UBE2J1, PNPLA3 and PAPPA indicates that the patient has example, RNA levels of the biomarker can be determined. suffered or is at risk of experiencing TIA. The RNA can be mRNA, rRNA, tRNA or microRNA 0014. In some embodiments, a decreased expression level (miRNA). In some embodiments, the level of RNA expres of one or more or all TIA-associated biomarkers selected sion is determined using a microarray. from the group consisting of ATG9B, DIP2C, EDAR, 0022. In some embodiments, the level of expression is GSTM1, GUSBL2, SMURF2, ZNF512B indicates that the determined by detecting hybridization of an TIA-associated patient has suffered or is at risk of experiencing TIA. gene probe to gene transcripts of the biomarkers in the bio 0015. In some embodiments, a decreased expression level logical sample. of one or more or all TIA-associated biomarkers selected 0023.
Load more

Recommended publications
  • AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI3A9] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA503371 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI3A9] Product data: Product Type: Primary Antibodies Clone Name: OTI3A9 Applications: FC, WB Recommended Dilution: WB 1:2000, FLOW 1:100 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG2b Clonality: Monoclonal Immunogen: Full length human recombinant protein of human AK4(NP_037542) produced in HEK293T cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 25.1 kDa Gene Name: adenylate kinase 4 Database Link: NP_037542 Entrez Gene 11639 MouseEntrez Gene 29223 RatEntrez Gene 205 Human P27144 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI3A9] – TA503371 Background: This gene encodes a member of the adenylate kinase family of enzymes. The encoded protein is localized to the mitochondrial matrix. Adenylate kinases regulate the adenine and guanine nucleotide compositions within a cell by catalyzing the reversible transfer of phosphate group among these nucleotides. Five isozymes of adenylate kinase have been identified in vertebrates.
    [Show full text]
  • AK3L1 Antibody - Middle Region Rabbit Polyclonal Antibody Catalog # AI12098
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 AK3L1 antibody - middle region Rabbit Polyclonal Antibody Catalog # AI12098 Specification AK3L1 antibody - middle region - Product Information Application WB Primary Accession P27144 Other Accession NM_001005353, NP_001005353 Reactivity Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Horse, Bovine, Guinea Pig, Dog Predicted Pig, Dog WB Suggested Anti-AK3L1 Antibody Titration: Host Rabbit 2.5μg/ml Clonality Polyclonal Positive Control: Jurkat cell lysate Calculated MW 25kDa KDa AK3L1 antibody - middle region - Additional Information AK3L1 antibody - middle region - References Gene ID 205 Noma,T.,Biochem.J.358(PT1),225-232(2001)Re Alias Symbol AK3, AK4, AK3L1, constitutionandStorage:Forshorttermuse,storea AK3L2 t2-8Cupto1week.Forlongtermstorage,storeat-2 Other Names 0Cinsmallaliquotstopreventfreeze-thawcycles. Adenylate kinase 4, mitochondrial {ECO:0000255|HAMAP-Rule:MF_03170}, AK 4 {ECO:0000255|HAMAP-Rule:MF_03170}, 2.7.4.10 {ECO:0000255|HAMAP-Rule:MF_03170}, 2.7.4.6 {ECO:0000255|HAMAP-Rule:MF_03170}, Adenylate kinase 3-like {ECO:0000255|HAMAP-Rule:MF_03170}, GTP:AMP phosphotransferase AK4 {ECO:0000255|HAMAP-Rule:MF_03170}, AK4 {ECO:0000255|HAMAP-Rule:MF_03170} Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Reconstitution & Storage Add 100 ul of distilled water. Final anti-AK3L1 antibody concentration is 1 Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. Precautions AK3L1 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.
    [Show full text]
  • Adenylate Kinase 4 Rabbit Mab
    Leader in Biomolecular Solutions for Life Science Adenylate kinase 4 Rabbit mAb Catalog No.: A2383 Recombinant Basic Information Background Catalog No. This gene encodes a member of the adenylate kinase family of enzymes. The encoded A2383 protein is localized to the mitochondrial matrix. Adenylate kinases regulate the adenine and guanine nucleotide compositions within a cell by catalyzing the reversible transfer Observed MW of phosphate group among these nucleotides. Five isozymes of adenylate kinase have 27kDa been identified in vertebrates. Expression of these isozymes is tissue-specific and developmentally regulated. A pseudogene for this gene has been located on Calculated MW chromosome 17. Three transcript variants encoding the same protein have been 25kDa identified for this gene. Sequence alignment suggests that the gene defined by NM_013410, NM_203464, and NM_001005353 is located on chromosome 1. Category Primary antibody Applications WB, IHC, IF Cross-Reactivity Human, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 205 P27144 IHC 1:50 - 1:200 Immunogen 1:50 - 1:200 IF A synthesized peptide derived from human Adenylate kinase 4. Synonyms AK4; AK 4; AK3; AK3L1; AK3L2; adenylate kinase 4 Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using Adenylate kinase 4 antibody (A2383) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane.
    [Show full text]
  • AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI7E5] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA503010 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI7E5] Product data: Product Type: Primary Antibodies Clone Name: OTI7E5 Applications: FC, IF, WB Recommended Dilution: WB 1:2000, IF 1:100, FLOW 1:100 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human AK4 (NP_037542) produced in HEK293T cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 0.38 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 25.1 kDa Gene Name: adenylate kinase 4 Database Link: NP_037542 Entrez Gene 11639 MouseEntrez Gene 29223 RatEntrez Gene 205 Human P27144 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI7E5] – TA503010 Background: This gene encodes a member of the adenylate kinase family of enzymes. The encoded protein is localized to the mitochondrial matrix. Adenylate kinases regulate the adenine and guanine nucleotide compositions within a cell by catalyzing the reversible transfer of phosphate group among these nucleotides. Five isozymes of adenylate kinase have been identified in vertebrates.
    [Show full text]
  • Anti-AK4 Antibody (ARG54902)
    Product datasheet [email protected] ARG54902 Package: 100 μl anti-AK4 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes AK4 Tested Reactivity Hu, Ms Tested Application ICC/IF, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name AK4 Antigen Species Human Immunogen Recombinant protein of Human AK4 (NP_001005353.1) Conjugation Un-conjugated Alternate Names EC 2.7.4.10; AK3; GTP:AMP phosphotransferase AK4; AK3L2; AK3L1; EC 2.7.4.6; AK 4; Adenylate kinase 4, mitochondrial; Adenylate kinase 3-like Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse kidney and HepG2 Calculated Mw 25 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 11639 Mouse GeneID: 205 Human Swiss-port # P27144 Human Swiss-port # Q9WUR9 Mouse Gene Symbol AK4 Gene Full Name adenylate kinase 4 Background This gene encodes a member of the adenylate kinase family of enzymes.
    [Show full text]
  • AK3L1 (AK4) (NM 013410) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC220572 AK3L1 (AK4) (NM_013410) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: AK3L1 (AK4) (NM_013410) Human Tagged ORF Clone Tag: Myc-DDK Symbol: AK4 Synonyms: AK3; AK3L1; AK3L2; AK 4 Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC220572 representing NM_013410 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGCTTCCAAACTCCTGCGCGCGGTCATCCTCGGGCCGCCCGGCTCGGGCAAGGGCACCGTGTGCCAGA GGATCGCCCAGAACTTTGGTCTCCAGCATCTCTCCAGCGGCCACTTCTTGCGGGAGAACATCAAGGCCAG CACCGAAGTTGGTGAGATGGCAAAGCAGTATATAGAGAAAAGTCTTTTGGTTCCAGACCATGTGATCACA CGCCTAATGATGTCCGAGTTGGAGAACAGGCGTGGCCAGCACTGGCTCCTTGATGGTTTTCCTAGGACAT TAGGACAAGCCGAAGCCCTGGACAAAATCTGTGAAGTGGATCTAGTGATCAGTTTGAATATTCCATTTGA AACACTTAAAGATCGTCTCAGCCGCCGTTGGATTCACCCTCCTAGCGGAAGGGTATATAACCTGGACTTC AATCCACCTCATGTACATGGTATTGATGACGTCACTGGTGAACCGTTAGTCCAGCAGGAGGATGATAAAC CCGAAGCAGTTGCTGCCAGGCTAAGACAGTACAAAGACGTGGCAAAGCCAGTCATTGAATTATACAAGAG CCGAGGAGTGCTCCACCAATTTTCCGGAACGGAGACGAACAAAATCTGGCCCTACGTTTACACACTTTTC TCAAACAAGATCACACCTATTCAGTCCAAAGAAGCATAT ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT ACAAGGATGACGACGATAAGGTTTAA This product is to be used for laboratory only. Not for diagnostic or therapeutic
    [Show full text]
  • AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI1H1] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA503199 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI1H1] Product data: Product Type: Primary Antibodies Clone Name: OTI1H1 Applications: FC, IF, IHC, WB Recommended Dilution: WB 1:2000, IHC 1:150, IF 1:100, FLOW 1:100 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human AK4(NP_037542) produced in HEK293 cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 0.24 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 25.1 kDa Gene Name: adenylate kinase 4 Database Link: NP_037542 Entrez Gene 11639 MouseEntrez Gene 29223 RatEntrez Gene 205 Human P27144 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 AK3L1 (AK4) Mouse Monoclonal Antibody [Clone ID: OTI1H1] – TA503199 Background: This gene encodes a member of the adenylate kinase family of enzymes. The encoded protein is localized to the mitochondrial matrix. Adenylate kinases regulate the adenine and guanine nucleotide compositions within a cell by catalyzing the reversible transfer of phosphate group among these nucleotides.
    [Show full text]
  • Research2007herschkowitzetvolume Al
    Open Access Research2007HerschkowitzetVolume al. 8, Issue 5, Article R76 Identification of conserved gene expression features between comment murine mammary carcinoma models and human breast tumors Jason I Herschkowitz¤*†, Karl Simin¤‡, Victor J Weigman§, Igor Mikaelian¶, Jerry Usary*¥, Zhiyuan Hu*¥, Karen E Rasmussen*¥, Laundette P Jones#, Shahin Assefnia#, Subhashini Chandrasekharan¥, Michael G Backlund†, Yuzhi Yin#, Andrey I Khramtsov**, Roy Bastein††, John Quackenbush††, Robert I Glazer#, Powel H Brown‡‡, Jeffrey E Green§§, Levy Kopelovich, reviews Priscilla A Furth#, Juan P Palazzo, Olufunmilayo I Olopade, Philip S Bernard††, Gary A Churchill¶, Terry Van Dyke*¥ and Charles M Perou*¥ Addresses: *Lineberger Comprehensive Cancer Center. †Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. ‡Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA. reports §Department of Biology and Program in Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. ¶The Jackson Laboratory, Bar Harbor, ME 04609, USA. ¥Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. #Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA. **Department of Pathology, University of Chicago, Chicago, IL 60637, USA. ††Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. ‡‡Baylor College of Medicine, Houston, TX 77030, USA. §§Transgenic Oncogenesis Group, Laboratory of Cancer Biology and Genetics. Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, MD 20892, USA. Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Section of Hematology/Oncology, Department of Medicine, Committees on Genetics and Cancer Biology, University of Chicago, Chicago, IL 60637, USA.
    [Show full text]
  • Screen for Kinases Affecting Amyloidogenic Cleavage by BACE1
    Screen for kinases affecting amyloidogenic cleavage by BACE1 Dissertation zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) an der Universität Konstanz Mathematisch-Naturwissenschaftliche Sektion Fachbereich Biologie vorgelegt von Stephan Penzkofer Konstanz, Juli 2011 Tag der mündlichen Prüfung: 24.10.2011 1. Referent: Professor Dr. Marcel Leist 2. Referent: Professor Dr. Daniel Dietrich Summary: The Amyloid β peptide (Aβ) is suspected to be a causal agent for Alzheimer’s disease (AD). Therefore a screen for kinases downregulating the initial step of its production, the cleavage of the Amyloid Precursor Protein (APP) by Beta-site of APP Cleaving Enzyme 1 (BACE1), was conducted in this study. Briefly, HEK293 cells were colipofected with one of in total 1357 siRNAs against 60% of the human kinome and either an APP construct with only the β-cleavage site left or normally cleavable APP as control. Remaining β-cleavage was for logistic reasons firstly measured with an activity-test for secreted alkaline phosphatase (SEAP) fused to both types of APP and subjected to Aβ-ELISA when interesting. Before the screen, the APP-constructs were characterized in the cell types HEK293 and CGCs with regards to cleavage, especially by BACE1. The screen resulted in 38 hits of which one, Testis Specific Serine Kinase 3, was confirmed once more. In a second, bioinformatic project, an initially suspected APLP-like pseudogenic-like sequence in C3orf52 was refuted. Further, analysis of C3orf52 gene expression data hints on a role in myeloid leukemia. Lastly, the phylogenetic relationship of the APP family paralogs was examined, also in comparison to neighboring gene families, and found in the topology (APLP1)(APLP2/APP).
    [Show full text]
  • Human Adenylate Kinase 4 / AK4 (1-223, His-Tag) - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AR09820PU-N Human Adenylate kinase 4 / AK4 (1-223, His-tag) - Purified Alternate names: AK3, AK3L1, ATP-AMP transphosphorylase, Adenylate kinase 3-like Quantity: 0.1 mg Concentration: 1.0 mg/ml (determined by Bradford assay) Background: AK4 (adenylate kinase 4) is a member of the adenylate kinase family of enzymes. This protein is localized to the mitochondrial matrix. Adenylate kinases regulate the adenine and guanine nucleotide compositions within a cell by catalyzing the reversible transfer of phosphate group among these nucleotides. Inherited mutations leading to AK4 deficiencies in erythrocytes have been implicated in hemolytic anemia. Uniprot ID: P27144 NCBI: NP_001005353 GeneID: 205 Species: Human Source: E. coli Format: State: Liquid purified protein Purity: >90% Buffer System: 20mM Tris-HCl buffer (pH 8.0) containing 10% glycerol, 2mM DTT, 0.1M NaCl Description: Recombinant human AK4 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. AA Sequence: MGSSHHHHHH SSGLVPRGSH MASKLLRAVI LGPPGSGKGT VCQRIAQNFG LQHLSSGHFL RENIKASTEV GEMAKQYIEK SLLVPDHVIT RLMMSELENR RGQHWLLDGF PRTLGQAEAL DKICEVDLVI SLNIPFETLK DRLSRRWIHP PSGRVYNLDF NPPHVHGIDD VTGEPLVQQE DDKPEAVAAR LRQYKDVAKP VIELYKSRGV LHQFSGTETN KIWPYVYTLF SNKITPIQSK EAY Molecular weight: 27.4 kDa (243aa), confirmed by MALDI-TOF (Molecular size on SDS- PAGE will appear higher). Storage: Store undiluted at 2-8°C for up to two weeks or (in aliquots) at -20°C or -70°C for longer.
    [Show full text]
  • A High-Throughput Study in Melanoma Identifies Epithelial- Mesenchymal Transition As a Major Determinant of Metastasis
    Research Article A High-Throughput Study in Melanoma Identifies Epithelial- Mesenchymal Transition as a Major Determinant of Metastasis Soledad R. Alonso,1 Lorraine Tracey,1 Pablo Ortiz,4 Beatriz Pe´rez-Go´mez,5 Jose´ Palacios,1 Marina Polla´n,5 Juan Linares,6 Salvio Serrano,7 Ana I. Sa´ez-Castillo,6 Lydia Sa´nchez,2 Raquel Pajares,2 Abel Sa´nchez-Aguilera,1 Maria J. Artiga,1 Miguel A. Piris,1 and Jose´ L. Rodrı´guez-Peralto3 1Molecular Pathology Programme and 2Histology and Immunohistochemistry Unit, Centro Nacional de Investigaciones Oncolo´gicas; Departments of 3Pathology and 4Dermatology, Hospital Universitario 12 de Octubre; 5Centro Nacional de Epidemiologı´a, Instituto de Salud Carlos III, Madrid, Spain; and Departments of 6Pathology and 7Dermatology, Hospital Universitario San Cecilio, Granada, Spain Abstract with a less favorable prognosis as potential candidates for adjuvant Metastatic disease is the primary cause of death in cutaneous or novel therapies. malignant melanoma (CMM) patients. To understand the Currently, the prognosis of primary CMM is mainly based mechanisms of CMM metastasis and identify potential on histopathologic criteria. The most important of these is the predictive markers, we analyzed gene-expression profiles of Breslow index, although it is merely a measure of tumor depth. 34 vertical growth phase melanoma cases using cDNA micro- New molecular markers that correlate with melanoma genesis and/or progression are continuously being identified but, to date, arrays. All patients had a minimum follow-up of 36 months. Twenty-one cases developed nodal metastatic disease and 13 most of them have been obtained in experimental models and did not.
    [Show full text]
  • ARB Dissertation
    Molecular Stratification and Characterization of Clear Cell Renal Cell Carcinoma Angela Rose Brannon A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Curriculum in Genetics and Molecular Biology. Chapel Hill 2010 Approved by: W. Kimryn Rathmell, MD, PhD Adrienne Cox, PhD William Kim, MD Charles Perou, PhD Kristy Richards, MD, PhD ©2010 Angela Rose Brannon ALL RIGHTS RESERVED ii ABSTRACT ANGELA ROSE BRANNON: Molecular Stratification and Characterization of Clear Cell Renal Cell Carcinoma (Under the direction of W. Kimryn Rathmell, MD, PhD) It is estimated that there will be 58,240 new diagnoses of kidney cancer in 2010. Most cases will be clear cell renal cell carcinoma (ccRCC) and have little information as to how their disease will progress. This diversity of disease natural history is especially noteworthy in a disease so well characterized by the inactivation of the von Hippel Lindau (VHL) tumor suppressor and resulting stabilization of Hypoxia Inducible Factors (HIF). Previous studies had suggested the presence of two or more clusters in ccRCC. Based on the nonuniformity within the disease’s natural progression and previous research, we hypothesized that distinct inherent molecular subclasses of ccRCC must exist and, therefore, sought to define and characterize them. In fact, two robust subtypes of ccRCC were identified, designated ccA and ccB. These subtypes are associated with survival by multivariate analysis, conferring a median survival of 8.6 years versus 2 years, respectively. We postulated that the underlying molecular pathways within the data would explain the survival difference.
    [Show full text]